Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

The Colors Beneath: More Than a Skin Condition

Yan MJ, Chou PP, Roberts AM, Jeong CY, Johnsen N, Katz A, Ma EJ, Nong Y, Armstrong AW. The Colors Beneath: More Than a Skin[...]

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

Holtsche MM, van Beek N, Hammers CM, Vorobyev A, Kasperkiewicz M, Schumacher N, Muck P, Schmidt E. Adjuvant therapy of severe and/or refractory bullous pemphigoid[...]

Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors

Wu M, Yang S, Yang Z, Fan J, Lomeli SH, Dharanipragada P, Moriceau G, Damoiseaux R, Kelley MC, Prieto-Granada CN, Giubellino A, Nosrati M, Kashani-Sabet[...]